DPP-4 Inhibitors as a savior for COVID-19 patients with diabetes

Area of Science:

• Endocrinology
• Virology
• Pharmacology

Background:

• Diabetic patients face heightened risks from COVID-19.
• Dipeptidyl peptidase-4 (DPP-4) regulates insulin and is targeted by DPP-4 inhibitors (DPP-4is) for diabetes management.
• DPP-4is possess anti-inflammatory and anti-hypertension properties.

Purpose of the Study:

• To review the potential of DPP-4 inhibitors as repurposed drugs against SARS-CoV-2.
• To assess the efficacy of DPP-4is in mitigating COVID-19 severity in diabetic patients.

Main Methods:

• Literature review of studies on DPP-4, SARS-CoV-2 spike glycoprotein interactions.
• Analysis of research on DPP-4 inhibitor mechanisms and effects.
• Synthesis of evidence regarding DPP-4is' impact on cytokine storm and viral entry.

Main Results:

• DPP-4 is identified as a potential entry point for SARS-CoV-2.
• DPP-4is may reduce the 'cytokine storm' associated with severe COVID-19.
• DPP-4is could potentially inhibit viral entry into host cells.

Conclusions:

• DPP-4 inhibitors show promise as repurposed therapeutics for COVID-19 in diabetic populations.
• Further investigation into DPP-4is could lead to novel strategies for managing severe COVID-19 complications in diabetes.
• Targeting DPP-4 may offer a dual benefit of glycemic control and antiviral effects.